Impact of pretreatment thrombocytosis on survival in primary breast cancer
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Summary: Platelet count has been reported to have predictive value in various cancer entities. In the case of breast cancer, evidence about involvement of platelets is still incomplete. Our objective was to assess the influence of pretreatment thrombocytosis on survival and establish its prognostic relevance for breast cancer patients. We performed a retrospective, multivariate analysis of 4,300 patients with early-stage breast cancer. All subjects participated in one of five prospective, randomized, multicenter trials conducted by the Austrian Breast and Colorectal Cancer Study Group. Thrombocytosis was defined as a platelet count exceeding 400 G/L. Median follow-up was 52 months. Univariate and multiple Cox regression models were calculated for overall survival (OS), breast cancer-related survival and disease-free survival (DFS). Pretreatment thrombocytosis was observed in 161 patients (3.7%). Estimated median OS, breast cancer-related survival and DFS for patients with versus those without thrombocytosis was 71.0 versus 99.5, 72.0 versus 100.9, and 80.4 versus 88.4 months, respectively (p = 0.0054, p = 0.0095, p = 0.0199). A multiple Cox regression model including tumor and nodal status, grading, age, hormone receptor status and pretreatment thrombocytosis identified pretreatment thrombocytosis as an independent predictive factor for OS (p = 0.0064) and breast cancer-related survival (p = 0.0162). Multivariate analysis failed to identify pretreatment thrombocytosis as an independent risk factor for DFS (p = 0.1355). In our retrospective study, elevated platelet counts at time of diagnosis were associated with poor prognosis in breast cancer. We hypothesize that platelets may contribute to the patho-physiology of hematogenous metastasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schmitter, D., Lauber, B., Fagg, B., & Stahel, R. A. (1992) · International Journal of Cancer · doi:10.1002/ijc.2910510220 · Cited by 133 · cited 1×
“One possible candidate is interleukin 6, since blood levels are reported to be high in malignant disease (36, 49, 50) and interleukin 6 is produced by various non-hematological cancer entities (51-55).”
Background
Cited by
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994
Contribution of platelets to tumour metastasis
Gay, L. J., & Felding-Habermann, B. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3004 · Cited by 1,645
Ratajczak, J., Wysoczynski, M., Hayek, F., Janowska-Wieczorek, A., & Ratajczak, M. Z. (2006) · Leukemia · doi:10.1038/sj.leu.2404296 · Cited by 1,340
Roxburgh, C. S., & McMillan, D. C. (2010) · Future Oncology · doi:10.2217/fon.09.136 · Cited by 998
The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis
McAllister, S. S., & Weinberg, R. A. (2014) · Nature Cell Biology · doi:10.1038/ncb3015 · Cited by 966
Metadata
- Authors
- Salat, A., Gnant, M., Kwasny, W., Mlineritsch, B., Menzel, R.-C., Schmid, M., Smola, M., Stierer, M., Tausch, C., Galid, A., Steger, G., Jakesz, R., & Taucher, S.
- Venue
- Thrombosis and Haemostasis
- Publisher
- Georg Thieme Verlag KG
- Published
- 2003
- Volume
- 89
- Issue
- 06
- Pages
- 1098-1106
- ISSN
- 0340-6245 (ISSN-L)
- 2567-689X
- OpenAlex
- W2246634871
- Cited by
- 157
- References
- 1
- FWCI
- 1.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of pretreatment thrombocytosis on survival in primary breast cancer. https://app.cochat.ai/papers/10.1055/s-0037-1613413
- The paper
- Salat, A., Gnant, M., Kwasny, W., Mlineritsch, B., Menzel, R.-C., Schmid, M., Smola, M., Stierer, M., Tausch, C., Galid, A., Steger, G., Jakesz, R., & Taucher, S. (2003). Impact of pretreatment thrombocytosis on survival in primary breast cancer. Thrombosis and Haemostasis. https://doi.org/10.1055/s-0037-1613413
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.